Dr Reddys launches generic version of Cuprimine Capsules in US
Penicillamine USP is a chelating agent used in the treatment of Wilson's disease.
Hyderabad and Princeton: Hyderabad-based drugmaker Dr Reddy's Laboratories Ltd. has recently announced that the company has launched Penicillamine Capsules USP, 250 mg.
The product is a therapeutic equivalent generic version of Cuprimine (penicillamine) Capsules, 250 mg, approved by the U.S. Food and Drug Administration (USFDA).
Dr Reddy's Penicillamine Capsules, USP is available as 250 mg capsules in a bottle count sizes of 100.
Penicillamine USP is a chelating agent used in the treatment of Wilson's disease. It is also used to reduce cystine excretion in cystinuria and to treat patients with severe, active rheumatoid arthritis unresponsive to conventional therapy.
Cuprimine is a trademark of Bausch Health Companies Inc.
The Cuprimine brand and generic market had U.S. sales of approximately $80 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.
Dr Reddy's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
The Company's markets include – USA, India, Russia & CIS countries, and Europe.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.